The effect of Emdogain on changes in cytokine profile during early wound healing

Phase 4

Completed

• Conditions: Generalized severe chronic periodontitis; Oral Health

• Registration Number: ISRCTN13262303
• Lead Sponsor: Regional Committees for Medical and Health Research Ethics (REK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-02-22
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Aged between 25 and 75 years
2. Non-smoking
3. No use of antibiotics over the previous 6 months prior to treatment
4. The presence of one pair of interproximal sites with probing pocket depth (PPD) of 6 mm or more, horizontal and/or vertical bone loss as demonstrated by the probing measurement and radiographic assessments following the initial phase of periodontal treatment
5. Experimental teeth must either have a vital pulp or, if subjected to root canal treatment, be asymptomatic, and without technical remarks
6. Prior to the start of the trial, the patients will give informed consent

Exclusion Criteria

1. Patients with a systemic condition like diabetes mellitus, cancer, HIV, disorders that compromise wound healing, chronic high dose steroid therapy, bone metabolic disease, radiation or immune-suppressive therapy
2. Patients with acute infectious lesions in the area of intended therapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cytokine levels in gingival fluid are measured using the Luminex-200 system (multiplex bead-based immunoassay) at baseline, 7 and 14 days postoperatively.